{"id":1665,"date":"2020-01-17T17:51:13","date_gmt":"2020-01-17T22:51:13","guid":{"rendered":"https:\/\/www.bumc.bu.edu\/rheumatology\/?page_id=1665"},"modified":"2020-01-17T18:04:20","modified_gmt":"2020-01-17T23:04:20","slug":"establishing-the-value-of-treatment-strategies-in-spondyloarthritis-the-valspa-study","status":"publish","type":"page","link":"https:\/\/www.bumc.bu.edu\/rheumatology\/research\/clinical-trials\/establishing-the-value-of-treatment-strategies-in-spondyloarthritis-the-valspa-study\/","title":{"rendered":"Establishing the Value of Treatment Strategies in Spondyloarthritis: The ValSpA Study"},"content":{"rendered":"<p><span>This work assesses patient preferences related to spondyloarthritis medications through patient focus groups and discrete choice experiments. A subsequent cost-effectiveness model will incorporate patient values with literature-derived estimates for medication effects, side effect rates, and costs. The hypothesis is that more expensive biological agents are not cost-effective as first line therapy for spondyloarthritis.<\/span><br \/>\n<em>PI: Maureen Dubreuil<\/em><br \/>\n<em>Funded by NIH\/NIAMS K23 AR069127. Funding period: 2016-2021<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>This work assesses patient preferences related to spondyloarthritis medications through patient focus groups and discrete choice experiments. A subsequent cost-effectiveness model will incorporate patient values with literature-derived estimates for medication effects, side effect rates, and costs. The hypothesis is that more expensive biological agents are not cost-effective as first line therapy for spondyloarthritis. PI: Maureen [&hellip;]<\/p>\n","protected":false},"author":14042,"featured_media":0,"parent":1232,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/rheumatology\/wp-json\/wp\/v2\/pages\/1665"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/rheumatology\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/rheumatology\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/rheumatology\/wp-json\/wp\/v2\/users\/14042"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/rheumatology\/wp-json\/wp\/v2\/comments?post=1665"}],"version-history":[{"count":1,"href":"https:\/\/www.bumc.bu.edu\/rheumatology\/wp-json\/wp\/v2\/pages\/1665\/revisions"}],"predecessor-version":[{"id":1666,"href":"https:\/\/www.bumc.bu.edu\/rheumatology\/wp-json\/wp\/v2\/pages\/1665\/revisions\/1666"}],"up":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/rheumatology\/wp-json\/wp\/v2\/pages\/1232"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/rheumatology\/wp-json\/wp\/v2\/media?parent=1665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}